Effect of Untact Upper Extremity Rehabilitation Using a Smart Board for Late Subacute and Chronic Patients with Brain Disorder
Launched by SAMSUNG MEDICAL CENTER · Feb 14, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a new way to help patients with brain disorders improve their arm function at home. Researchers want to see how effective and safe it is to use a special device called the Neofect Smart Board for rehabilitation compared to traditional therapy methods. The study will involve patients who have had issues with their arm movement due to neurological conditions like stroke or brain injuries for at least three months.
To participate, individuals must be between 19 and 85 years old and have some weakness in one arm. They should be able to understand simple instructions and perform tasks with the smart board. However, those with certain severe conditions or disabilities that could interfere with the rehabilitation process will not be eligible. If you join, you can expect to work on exercises using the smart board to help regain strength and function in your arm, all from the comfort of your home.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with neurological diseases aged 19 to 85 years old
- • Patients with hemiparesis lasting for more than 3 months due to neurological diseases (stroke, traumatic brain injury, brain tumor) and impaired upper limb function
- • Patients with shoulder flexor and adductor muscle strength of MRC grade 2 or higher
- • Patients with shoulder extensor and abductor spasticity of MAS grade 1+ or lower
- • Participants with sufficient cognitive function to understand the instructions from the researcher and the smart board, and to perform the tasks (K-MMSE ≥21)
- Exclusion Criteria:
- • pre-existing significant neurogenic disorders
- • major psychiatric disorders such as schizophrenia, bipolar disorder, or dementia
- • History of diseases that caused pain or muscle atrophy in the affected upper limb before the onset of the neurological disease, which interfered with rehabilitation
- • Severe spasticity of the affected upper limb (Modified Ashworth Scale score ≥3)
- • skin disorders or open wounds on the affected upper limb
- • Amputation, fractures, or soft tissue-related diseases or injuries on the affected upper limb
- • severe pain that interferes with rehabilitation of the affected upper limb (Numeric Rating Scale \> 6)
- • Inability to maintain a seated posture for more than 10 minutes, which is required for using the smart board
- • Significant visual impairment to the extent that the screen cannot be recognized when using the smart board
About Samsung Medical Center
Samsung Medical Center (SMC) is a leading healthcare institution in South Korea, renowned for its commitment to advancing medical research and innovation. As a prominent clinical trial sponsor, SMC integrates cutting-edge technology and expert clinical practices to conduct rigorous studies aimed at improving patient outcomes. The center is dedicated to fostering collaborations with global research entities and adhering to the highest ethical standards, ensuring the integrity and reliability of its clinical trials. With a focus on diverse therapeutic areas, SMC plays a pivotal role in translating scientific discoveries into effective treatments, ultimately enhancing the quality of healthcare worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported